Mengxing You, Puyuan Xing, Junling Li. "High-dose furmonertinib in
                    <i>EGFR</i>
                    -mutated advanced NSCLC with brain metastases after EGFR-TKI resistance: The iFORCE phase II trial.." Journal of Clinical Oncology (2026). https://doi.org/10.1200/jco.2026.44.16_suppl.8607